Feng Liu

Company: Pfizer

Job title: Director

Seminars:

Using ctDNA to Guide Clinical Decision Making in Phase I Oncology Trials 2:30 pm

ctDNA can be more useful than tumor tissue in identification or screening patients ctDNA can be a PD biomarker as well early indicator of clinical efficacy Longitudinal monitoring emerging tumor gene alterations in ctDNA can help understand resistance mechanisms and guide patient managementRead more

day: Day Two